Company Overview

Sakar Healthcare Limited, incorporated in March 2004, is a prominent pharmaceutical company based in India that operates in the manufacturing, research, and development of pharmaceutical products. Originally incorporated as a private limited company, it transitioned to a public limited company on March 27, 2015. The company is promoted by Sanjay Shah, Rita Shah, and Aarsh Shah, with Sanjay S Shah serving as Chairman and Managing Director.

The company holds several key certifications including ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and National Drug Authority approvals, demonstrating its commitment to quality standards in pharmaceutical manufacturing. Operating in over 50 countries globally, Sakar Healthcare has established a robust international presence with 292 registered products and 210 more products under registration, partnering with more than 70 overseas distributors.

Business Operations and Product Portfolio

Sakar Healthcare specializes in manufacturing diverse pharmaceutical products including liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectables (SVP) in ampoules, vials and lyophilized injections, oral solid dosages, along with research and development of these products. The company's product portfolio includes Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid and Lyophilised Injections (In Vials).

The company maintains an extensive therapeutic presence across approximately 22 therapeutic areas including antacid, antimalarial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins.

The company operates through multiple business models including contract manufacturing for leading domestic brands as well as direct sales in both domestic and export markets. Sakar Healthcare exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States.

Financial Performance

Full Year Performance (FY 2025)

For the full year ended March 2025, Sakar Healthcare reported strong financial performance with net profit rising 49.96% to Rs 17.50 crore compared to Rs 11.67 crore in the previous year ended March 2024. Sales increased 15.80% to Rs 177.58 crore versus Rs 153.35 crore in the previous year.

Q4 FY2025 Results

For the quarter ended March 2025, the company demonstrated robust growth with net profit surging 84.62% to Rs 5.76 crore against Rs 3.12 crore in the corresponding quarter of the previous year. Sales rose 16.67% to Rs 50.24 crore compared to Rs 43.06 crore in the same quarter of the previous year.

The company's EBITDA increased by 35.52% and earnings per share (EPS) rose to Rs 2.66 from Rs 1.46 in the previous year, reflecting improved operational efficiency and profitability.

Recent Quarter Performance (Q3 FY2025)

In the quarter ended December 2024, net profit rose 118.84% to Rs 4.53 crore compared to Rs 2.07 crore in December 2023, while sales increased 16.63% to Rs 43.42 crore from Rs 37.23 crore in the corresponding quarter of the previous year.

Market Position and Valuation

As of recent market data, Sakar Healthcare has a market capitalization of Rs 764 crore, positioning it as a mid-cap pharmaceutical company. The stock is trading at approximately 2.67 times its book value. Key financial ratios include a stock P/E of 43.6, book value of Rs 130, ROCE of 8.58%, ROE of 6.40%, and a face value of Rs 10.0. The P/B (price-to-book) ratio stands at 2.62.

The stock has recorded a 52-week high of Rs 374.50 and a 52-week low of Rs 210.10, indicating significant price volatility during the period.

Shareholding Pattern and Corporate Governance

Promoter holding in the company stands at 53.6%. Recent data shows promoter holding increased to 53.58% as of March 2025 from 53.15% as of June 2024. Importantly, there is no promoter pledging in Sakar Healthcare Limited, which indicates strong financial health of the promoters.

The company maintains a diversified board structure with multiple independent directors including Shailesh B Patel, Prashant C Srivastav, Hemendrakumar C Shah, and Jignesh Mukundbhai Parikh serving as Independent Non-Executive Directors.

Recent Corporate Developments

In June 2025, Sakar was granted its second EU marketing authorization for a colorectal cancer oncology injection, marking a significant expansion in its oncology portfolio. This development demonstrates the company's growing capabilities in specialized therapeutic areas and its commitment to expanding its international regulatory approvals.

The company has also entered into significant partnerships, including with ACCORD HEALTHCARE LTD., which operates in over 45 countries and ranks among the top-3 in most EU markets. This partnership involves technology transfer of 7 registered oncology products for supply to the UK, EU, and emerging markets.

Industry Position and Peer Comparison

Sakar Healthcare operates alongside industry peers including Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, and Zydus Lifesciences Ltd. The company belongs to the Health Care sector and Pharmaceuticals sub-sector, positioning it within India's growing pharmaceutical industry.

The company's focus on contract manufacturing, export markets, and specialized therapeutic areas positions it as a niche player in the pharmaceutical sector, with particular strength in injectable formulations and oncology products. With its WHO-GMP and EU-GMP certifications, Sakar Healthcare is well-positioned to capitalize on the growing global demand for high-quality pharmaceutical products manufactured in India.